Navigation Links
Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimer's Immunotherapy Programs
Date:11/8/2011

al trials.

IN-N01 is a proprietary product of the company's ANTISENILIN technology platform, which includes other products in development such as Bapineuzumab, which are being developed independently by major pharmaceutical companies.  IN-N01 has similar specificity for the beta amyloid toxin as does Bapineuzumab. However, in contrast to Bapineuzumab, IN-N01 may have reduced risk of inflammation from immune responses in patients.  In addition, IN-N01 is being developed as an antibody drug conjugate with OX2 under Intellect's new CONJUMAB-A platform technology.  This combination is expected to increase clearance of beta amyloid from the brain as well as reduce inflammation, which can result in vasogenic edema, a side-effect of immunotherapy in some patients that result from antibody-mediated dissolution of plaque.  The CONJUMAB-A platform for which IN-N01-OX2 is the flagship molecule, is applicable to a broad range of diseases including: Alzheimer's, Parkinson's, Huntington's, Age-Related Macular Degeneration, Glaucoma, Cerebral Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease, Cortical Basal Degeneration and Peripheral Amyloidosis.  

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease, and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes small neuroprotective molecules and neoepitope-based immunotherapy approaches including monoclonal antibodies and vaccines targeting beta amyloid and abnormal tau proteins. The company is currently developing three separate platform technologies:  ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology which underlies several products in advanced clinical development and is licensed to major pharmaceutical companies.  The company's RECALL-VAX
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
3. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
7. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
8. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
9. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
10. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
11. Limited Healthcare Infrastructure and Weak Intellectual Property Protection are Among the Challenges Pharma Faces with Emerging Market Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
(Date:9/22/2014)... Sept. 22, 2014  Elusys Therapeutics, Inc. (Elusys), ... infectious disease, today announced it has completed three ... obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development ... from these studies support the safety and tolerability ... the intended therapeutic dose. The conclusion of these ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... Alan Mozes HealthDay ... Pediatricians, take note: Many American parents are aware of online ... choose a pediatrician for their children, according to a new ... more than 1,600 parents -- further suggest that negative online ... that doctor has been recommended by a neighbor. Conversely, ...
(Date:9/22/2014)... a whole eye transplant seems futuristic, if not ... U.S. Department of Defense, researchers at University of ... someday make implantation of an entire, functional eye ... be a holy grail for vision restoration," said ... grant co-recipient with colleagues at University of Pittsburg ...
(Date:9/22/2014)... have found that an anticonvulsant drug may help in ... dozens of antibiotics target what bacteria do, their study ... are created, and they found there is a way ... as there is growing concern worldwide about how antibiotic ... World Health Organization has declared that antibiotic resistance is ...
(Date:9/22/2014)... 22, 2014 An inventor and anesthesiologist ... the problem of side-sleeping. "My lower arm always became ... designed a solution to this problem," she said. "It’s ... to have your arm 'fall asleep.'" , The Sleeping ... her side more comfortably. It avoids pain and restlessness ...
(Date:9/22/2014)... 2014 -- Recent two-generation approaches to reducing poverty ... increasing attention from researchers, advocates, and foundations. By ... them to move to jobs that offer a ... and education for children, these programs aim to ... according to a new report from the National ...
Breaking Medicine News(10 mins):Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Looking ahead: Whole eye transplant under development 2Health News:A two-generation lens: Current state policies fail to support families with young children 2
... WashingtonThe American College of Physicians (ACP) today applauded Rep. ... for their bipartisan introduction of the Medicare Physician Payment ... is designed to eliminate the flawed Sustainable Growth Rate ... scheduled cuts. The SGR cuts threaten to drive physicians ...
... Black Americans who suffer cardiac arrest in public places are ... automated external defibrillators, a new study has found. Cardiac ... to stop beating. CPR and automated external defibrillators (AEDs) -- ... a normal rhythm -- can help a cardiac arrest victim ...
... May 11 (HealthDay News) -- Heart attack survivors are more ... it,s safe, a new study shows. University of Chicago ... study. Among patients who were sexually active before their heart ... discharged from the hospital were 1.5 times more likely to ...
... Brophy Marcus HealthDay Reporter , FRIDAY, May ... their periods, but new research suggests weight-loss surgery can ... hair growth and skin problems that often accompany significant ... the United States," said study author Chandhana Paka, a ...
... mobility now have access to specialized exercise equipment in ... the University of Alberta and the Spinal Cord Injury ... electrical stimulation (FES) rehabilitation therapy machines are now available ... Faculty of Physical Education and Recreation at the U ...
... disease allow physicians to tailor treatment to a patient,s ... many types of cancer the molecular subtypes are more ... that can affect a patient,s response to therapy. ... the first time that lung cancer molecular subtypes correlate ...
Cached Medicine News:Health News:ACP applauds introduction of bipartisan bill to eliminate Medicare SGR formula 2Health News:Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study 2Health News:Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study 3Health News:Sex After Heart Attack? Doc's OK May Be Key 2Health News:Weight-Loss Surgery May Also Help Menstruation, Skin, Hair 2Health News:Weight-Loss Surgery May Also Help Menstruation, Skin, Hair 3Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3Health News:Molecular subtypes and genetic alterations may determine response to lung cancer therapy 2
... innovative stent allows the physician to intubate the ... with just topical anesthetic drops., ,The SRS is ... in three lengths 25mm, 30mm and 35mm (disposable ... stent is an anchor-shaped head to provide fixation. ...
... or somatomedin-C, is a peptide highly dependent ... promoting activity. IGF-I is transported in serum ... of growth disorders, measurements of IGF-I are ... hormone secretion. A normal plasma or serum ...
... is a high-throughput immunoassay system built around ... 2000 with the important addition of Logic ... to be designed for optimal performance with ... for critical assays such as the cardiac ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
Medicine Products: